White label ELPA - ClinicalTrials.eu

Study Comparing Regorafenib and Regorafenib-Irinotecan Combination for Patients with Metastatic Colorectal Cancer After Standard Treatments Have Failed

Not recruiting

3 1 1 1
Investigated diseases:
- Colorectal cancer metastatic
Investigated drugs:
- Irinotecan
- Regorafenib
Study of Pembrolizumab and Olaparib for Patients with Advanced Colorectal Cancer with DNA Repair Deficiency

Not recruiting

2 1 1 1
Investigated diseases:
- Colorectal cancer
Investigated drugs:
- Olaparib
- Pembrolizumab
Study on ADP-A2M4CD8 and Nivolumab for Patients with Recurrent Ovarian Cancer

Not recruiting

2 1 1 1
Investigated diseases:
- Ovarian cancer recurrent
Investigated drugs:
- Autologous T Cells Expressing Cd8A And A T-Cell Receptor Targeting Mage-A4
- Nivolumab
Study Comparing Risankizumab and Deucravacitinib for Adults with Moderate Plaque Psoriasis Eligible for Systemic Therapy

Not recruiting

3 1 1 1
Investigated diseases:
- Psoriasis
Investigated drugs:
- Deucravacitinib
- Risankizumab
+1
Study on Osimertinib and Chemotherapy for Patients with Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer

Not recruiting

3 1 1 1
Investigated diseases:
- Non-small cell lung cancer
- Non-small cell lung cancer metastatic
Investigated drugs:
Study on the Effectiveness and Tolerability of Oral vs. Subcutaneous Methotrexate for Patients with Early Rheumatoid Arthritis

Not recruiting

3 1 1 1
Investigated diseases:
- Rheumatoid arthritis
Investigated drugs:
- Methotrexate
Study of Capivasertib and Paclitaxel for Patients with Advanced or Metastatic Triple-Negative Breast Cancer

Not recruiting

3 1 1
Investigated diseases:
- Triple negative breast cancer
Investigated drugs:
- Capivasertib
- Paclitaxel
Study of ibrutinib and venetoclax combination therapy for patients with relapsed or refractory chronic lymphocytic leukemia who have adequate kidney function

Not recruiting

2 1 1 1
Investigated diseases:
- Chronic lymphocytic leukaemia
Investigated drugs:
- Ibrutinib
- Venetoclax
Study Comparing Pirtobrutinib with Idelalisib and Rituximab or Bendamustine and Rituximab for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Not recruiting

3 1 1 1
Investigated diseases:
- Chronic lymphocytic leukaemia
Investigated drugs:
+5
Study on Long-Term Safety and Efficacy of ARO-APOC3 for Adults with Mixed Dyslipidemia

Not recruiting

2 1 1
Investigated diseases:
- Type V hyperlipidaemia
Investigated drugs:
- Synthetic Double-Stranded Sirna Oligonucleotide Directed Against Apolipoprotein C-Iii Mrna And Covalently Linked To A Ligand Containing Three N-Acetylgalactosamine Residues

Full Name *

e-Mail *

Country Prefix *

Phone Number *

Nationality *

Gender *

Check all consents

Check all consents

I accept the Terms and Conditions and Privacy Policy *

*I accept the Terms and Conditions and Privacy Policy

I consent to receiving commercial information from the Service Operator *

*I consent to receiving commercial information from the Service Operator

I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes *

*I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes

We use cookies